Charity registration number 1194608 THE CANCER TREATMENT AND RESEARCH TRUST ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 Sob•ll RId•S LLP The Kinetic Centre Theobald Str&•t Elstree Borehamwood Hèrtfordshlr• WD6 4PJ
THE CANCER TREATMENT AND RESEARCH TRUST LEGALAND ADMINISTRATIVE INFORMATION Trustees Mr Russell Hallam Dr Paul Nathan DrA Sharrna Dr David Pinato Prof. Mithael Seckl Prof. Gordon Rusb'n Ms Kirandeep GWaI Dr Ehsan Ghorani Mr Glen Williams Professor Maraa Hall IAppointed 17 May 20261 IReliremenl 31 July 20251 Charlty number 1194608 Prlnclpal addr•s• Upper East Research Office Mount Vemon Hospital Rickmansworth Rood Northwc*>J HA6 2RN Ind•pgnd•nt •xamln•r Sobell Rhodes LLP The Kinétic Cèntrè Theobald Street Elslre& Borehamwocxj Hertfordshire Unitèd Kingdom WD64PJ
THE CANCER TREATMENT AND RESEARCH TRUST CONTENTS Page Trustees report Statèment of trust885 r8sponsibilitl85 14 Independent examinerfs report Statement of financial acts'vities 16 Balan¢¢ $hegt 17 Notes to the ffinanual slalements 18-29
THE CANCER TREATMENT AND RESEARCH TRUST TRUSTEES REPORT FOR THE YEAR ENDED 31 DECEMBER 2025 The tru5t8es hav8 adopted th8 provisions ol Ar£ounting 8nd Rew)rting by Charitle5.' Stat&m8nt of R8cornmended Practice applicable to charities preparing their accounts in accordance wth the Finanaal Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021 (effective 1 January 20191. STRUCTURE. GoveRNANCE, MANAGEMENT The Cancer Treatrnent and Research Trust ICTRTI which was founded in 1985, supports work mainly in the d8partm8nt5 of medical oncology at the W8St London Cancer Cenire bas8d at Charing Cr055 and Hammer5mith Hospitals Ilmperial College Healthcare NHS Trust) and in the department ol medical oncobjy at the Unt Vemon Cancer Cenlre, in Northwood, Middlesex. The charity is a Charitsble Incorporated Organisation ICIOI registered Ihe Charity Commission. 11 is govemed by its constituts¢n, and the irustees are re5ponsibl¢ ftr ensuring compliarbce with thai goveming document. The lomer unincorporated trust remains on the regisler solèly to manage rèsidual matters arising from the 2022 transition and does not undertake actsve operatns. Truste•s Thè eharity is govembd by 3 8oafd of Trusteès comprising individuals with professional baekgrounds in mèdicinè. law and other relevant disciplines. The Board indudes cancer specialists. reflectin9 the charity's principal objectives and research activities. Trustees are appoinied in accordance %•thh Ihe charity's constslution. New ¢nJsiee8 receive an induction covering thèir lègal duligs, govèmancè proeèssès, and th¢ charity's kèy poliuès. Trustees are required to dedare and manage any conflicts of interest in line with the charity's confllcts pollcy. In July 2025, Professor Marc4a Hall stepped down as a truslee of the charrty. AdmlnlJtrAtlon On 1st January 2022, CTRT offiaally transitioned to a Charilable Ino)rporated Organisalion ICIOI status. The original Canr Tatment and Research Trusl (charity number 2929091 remains registered as a charity with the Charity Commission. albeit it only remains aclive in order to manage any sIdUal matters following the 2022 Ir8nsitio)n. Charfty Manag•r The Charity Manager is spOnsible for Ihe day-lcrday cyeration ol ihe charity and manages its staff on behalf ol the Iruslees. Mrs Laura Brown has h8ld this positron srncè Junè 2021. During 2025. Mrs Fiankiè Brittan join8d th8 charity on a temporary basis to provi¢Je cover during Mrs Brown's per¥)d of leave. ObJ8ctlves and acllvltles The Cancer Treatment and Research Trust ICTRTI which was founded in 1985. supports work mainly In the departments of medical oncology at the West London Cancer Centre based at Charing Cross Hospital and in the department ol medical oncology al Ihe Mount Vernon Cancer Centre. in Northwood. Middlesex. The CTRT exists lo support treatment and research into many foThs of malignant disease and has been particularfy involved in understanding how Certain cancers dev8k)p, finding better ways to monitor them and developing new anti-cancgr agents. It remains committed to lunding r85earch that is rK>t Èd8qU8tely funded eith8r by th8 tnajor oncer charities such as CRUK, the MRC or the phamaceutical industry.
THE CANCER TREATMENT AND RESEARCH TRUST TRUSTEES REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025 The r8S88rch support8d by CTRT can rOlY 5pif( into th8 following ar88S'. Ovarian, uterine and rafe gynaecological cancers Lung Cancer Tests'cular and Ovarian Germ Cell Cancer Gestational Trophoblastic Di5ea5e M81anorna Renal Cancer Immunotherapyllmmunology Novel Therapies The trustees confimi that they have had due regard to the Charity Commission's guKlance on public benefrt when reviewing th8 charity's 8irn$. obiocbvos and actiwties. Aehlov•m•nt8 and rtornIaneé Significant 8CtAVItAes 8nd 8¢1Jiev8ments against obigctiv8$ The trustees are pleased with the achievements and perfomiance of the Trust in 2025. In 2025, r8sèareh, either fully or partly lund8d by CTRT. l•d lo 73 publication$. This included research which.. Led lo the first set ol glob81 consensus-ba5ed Irealmenl guidelines for GTD Updaied UK guidelines lor the manag¢moni of uv$al mlanoma Evaluated clinical outcomès in patiènts wilh mètastatic hom)on• sènsitlV8 proslalè cancar tr88t•d with triplet therapy (Darolutamide in combinalion with docetsxel chemotherapy and androgen deprivation therapy based on ARASENS trial resultsl Ilhe RECOMMEND study) Provided evidence from an expanded mvlti-centre lrial (phase 111 TOPAZ-11 which supports the adoption of durvalumab18n immunolher8Py treatment) in combin81ion wlh gerncilabine and cispl81in in routine dinic81 praciieè lor palianls wilh advancèd liary tract cancar. A lull list ol the pu1Shed papers is below.. Vengalil S. Mohammed R, Das P, Sharrn8 A. Vngalil K, Wickrarnasinghe K. Reid l R, Lim J H. Septèmbèr 2025. Annals of Onc013Y 36.. S1293 DOI". 10.101611.annonc.2025.08.2993. Amaral T, Nanz L, Hi9uiia LMS, Ascierto P, B8rking C, Cou5elo EM, Donia M, Durnrn8r R, GutZrn8r R, Haushild A, Jalving M, Loe R. Lorigan P, Maiquez-Rodas I, Michelin O. Nathan P, Rtsbèrt C, Sch8dendorf D, Sobczuk P, FlaQ L, Leiter U. Ga C. Eur J CatKer. 2025 Jan 17,'215. Singal AG, Salem R. Pinaio OJ, Pillai A. Gaslroenlerology. 2025 Sep'169141'.585-599. dim.. 10.10531 j.gastro.2025.03.047. Epub 2025 May 2. PMID.- 40320088. win J Hepatocell Carcinorna. Stef8r)ini B. Fulgenzi CAM, Scheiner B, Korolewicz J, Cheon J, Nishida N, Ang C. Marron TU, Wu YL, S8eed A, Wi8tham B. Rim8ssa L, Pirozzi A, Carnrnarota A, Pressiani T, Pinter M, Balcar L, Huang YH, Mehan A, Phen S, Vwaldi C, Salani F. Masi G, 8eth.nger D, Vogel A, Schanlein M, von Felden J, Schulze K, Wege H, Samson A, Galle PR, Kudo M, Manf1 GF, Celsa C, Awosika N, Cortellini A, Singal AG. Sharma R. Chon HJ. Tovoli F. Piscaglia F. Pinato DJ. DAessio A. 2025 Apr 4'.12.'671-683. doi.. 10.21471JHC.S462701. PMID.. 40201222.. PMCID.. PMC11977629.
THE CANCER TREATMENT AND RESEARCH TRUST TRUSTEES REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025 A hase 1b mutticentre d05e e5fdlation safe and hafrnacokinetscs stud ol tilvestarnab BG8149 la sed I tinum-resi rade sertsu ovarian ncer PROC alienl Sooi K, Tan TZ, Kim JW, Lee JY, Kim BG, Micklem D. Jackson A. Pinato DJ, Goutley C, Kristeleit R. Blagden SP, Bjorge L, Tan DSP Br J Cancer. 2025 Ocl..133161'.89&908. doi.. 10.10381s41416-025-03090-6. Epub 2025 Jul 22. PMID.. 40696160: PMCID.. PMC12449448. Celsa C. Pinato DJ. Cabibbo G. J Hepatol. 2026 Feb.'84121-'e77-e79. 10.1016tI.jhep.2025.10.009. Epub 2025 Oct 17. PMID.. 41110521. Ghidini M. Hahne JC. Senli C. Heide T. Proszek PZ. Shaikh R. Carter P. Hubank M. Trevisani F, Garrone O. Cappelle¢ti MR. Generali D, Cattaneo M. Gnocchi N. Donats G. Gobbi A. Grizzi G. Lampis A, El9hadi R, Tanzi G, Tornasello G, Ratti M, Pina¢o DJ, Fassan M. Vlachogiannis G. Sottoriva A, Cortellini A, P8S58lacqua R, Val8ri N. Clin Cancèr Res. 2025 Fab 17,"31141..707-718. doi." 10.11S8I1078432.CCR-24-O924. PMID.. 39688961. Seckl MJ, Kaur B. Ghorani E. Bergamini A. Mangili G. Int J Gynecol Cancer. 2025 M8r,'35131'.101670. doi.. 10.10161j.ijgc.2025.101670. Epub 2025 Jan 29. PMID.. 40020416. Vitale A, Kim JS, Cabibbo G. Casadei-Gardini A. lavarone M. Rimassa L. Ponziani FR, Tovoli F, Chon HJ, Kang B, Kim C. Imaoka H. Ikeda M. Kudo M. Aoki T. Tortora R. Guarracino M. Slelanini B, Marseglia M. SparacinoA. Celsa C, Bruccoleri M. Alimen¢i E. Marra F, Camp8ni C. Bhoori S. Mazzaferro V. Sacco R, Facciorusso A, Martini A, Stella L. Cerrilo L. Toyc¥Ya H. Yasud8 S, Rossari F, Rimini M, Suda G, Sho T, Masi G, Vivaldi C, Prèssiani T, Kakizaki S, N89anuma A, Avallone A, Nappi A. Vidili G, SoldA c. B&rgamo F. Pinato DJ. Pelizzaro F. Foschi FG, Secomandi A, Verderame F. Bronte E, Math'nelli E. Marino D. Grasselli S. Olivani A. Brunello MR. Damone F. Mega A. Marzi L. Tamburini E. Ramundo M, Federico P, Daniele B. Giannini EG. Pasla A. Morisco F. Guarino M. Hoyek C. Boninsegna S, Gupt8 A, Sacerdoti D, Oalbeni A. Calvo Ram¢)s I, Adev8 J, Saitta C. Pitronè C. L6ntJni Graziano ML, Farèlla N, Rendina M, Grassi T. R(xJnqu8nz MG. Maiello E. Presa J, Pinho l. Hiasa Y. Hirooka M. Chen J. Arrichiello G, Aschele C, Furlanetto A, Cillo U. Liver Cancer. 2025 Aug 5. doi.. 10.11591(X)0547792. Epub ahead of print. PMID.. 41063731; PMCID.. PMC12503878. vi S Mehrotra. A C Redla, J K Tan. A Ghose. A Maniam. S Boussios. G L Banna, P Das. S Adeleke, A Sharma, IUC24417-83 The Oncologist, Volume 30. Issue Supplement 1, September 2025, oyaf248.011, bl(p ctDNA.. A Gatewa alOllular Cancer Pinalo DJ, Lombardi P, D'Alessio A, TorkpM)ur A, Fulgenzi CAM, Brunetti L. Clin Cancer Res. 2025 Mar 17',31161.'955-957. doi.. 10.11581107&0432.CCR-24-3805. PMIO.. 39792474. aliz trattfirAti n in nt l tr h bl ti Seckl MJ, Ghorani E. Ann Oncol. 2025 Oct,"361101:1111-1112. diN." 10.10161j.annonc.2025.07.018. Erxjb 2025 Aug 6. PMID". 407746(MJ.
THE CANCER TREATMENT AND RESEARCH TRUST TRUSTEES REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025 D88 L88rnln Mod&l for Predictin Immunothera Res n58 in Adv8nced Non-small C811 Lun Canc8r Rakaee M, Tafavvoghi M, Ricaub" 8, AJe5si JV, Cortellini A. Citarella F, Nibid L, Perrone G, Adib E, Fulgenzi CAM, Hidalgo Filho CM, Di Federico A, Jabar F. Hashemi S, Houda I, Richardsen E, Rasmussen Busund LT, Donnem T, Bahce I, Pinato DJ, Helland A... Shdl LM, Awad MM. Kwiatkowski DJ. JAMA Oncol. 2025 Feb 1'.11121'.109-118. doi.. 0.10011jamaoncol.2024.5356. PMID.. 39724105.. PMCID.. PMC11843371.Qg2o r DNA chernoernbolization in he atocellular carrinoma Sharrna R, Alharbi SN, Ellum K, Motedayen-Aval L, CasadelardInl A, Pinato DJ, Bettinger D, Bengsch 8, Patel R, Evans J. NPJ Prec¢s Oncol. 2025 Jul 1".9111'.214. doi.. 10.10381 s4169&02&00961-2. PMID.. 40596669: PMCID.. PMC12218101. Savage P, Froeling F, Lythgoe M. Fishèr R, Maher G. Winter M. Erèméishvili K. Sarwar N, Aguiar X, Slngh K, Hancock B, Coleman R. Tidy J, Seckl MJ.J Obstet Gynaecol. 2025 0&c'.45111.'2571184. dd.. 10.1080101443615.2025.2571184. Epub 2025 Oct 16. PMID.. 41099823. rrnin rviv h fi Cortèllini A, Brunetti L. Di Fazio GR. Garbo E. Pinalo DJ. Nald) J. Katz A. Loza M. Near JW, Genova C. Getlinger S, Kim SY. Jayakrishnan R. El Zarif T. Russano M. Pecci F. Di Federico A. Awa(J M. Alessi JV, Montrone M. Owen DH. Signorelli D. Fler MJ. Li M. Camerini A, De Giglio A. Young L. Vincenzi B, Metro G, Passiglia F. Yendamuri S, Guida A. Ghidini M. Awosika NO. Napolrtano A. Fulgenzi CAM. Gri58nti S, Grossi F, D'lncecco A, J¢sephides E, Van Hernelrijck M, Russo A. Gelibter A, Spinelli G, Verrico M. Tom85ik 8, Giusli R, Newsom-Davis T, Bria E. Sebasiian M, Rosl M. Forster M, Mukhèrieè U. Landi L, Mazztsni F, Aujayeb A, Dupont M, Curioni-Fonlecedro A. Chiari R. Pantano F. Morabito A. Laonetti A. Friedlaender A. Addeo A, Zorallo F. De Tursi M. Canlini L. Roca E. Mountzios G. Oella Gravara L. Kalvapudi S, Inno 4 Bironzo P. Di Marco Barros R. O'Reilly D. Bell J. Karapanagiotou E. Monnet l. Baena J. Macerelli M, Majern M, Agusloni F, Cortinovis DL. Tonini G, Minuts G. Bennali C. Mezquits L. GorrAa T. Servelto A, Benin8to T, Lo Russo G, Rogado J, Moliner L. Biello F. Aboubakar Nana F, Dingernans AM, Atrrts JGJV, Fèrrara R, Torri V, Hèjlh TA, Tak8da K, Naqash AR, Gar8ssino M, P8tars S, W8kalaè H, Nass8r AH, Ricciuti 8. J Immunother Cancer. 2025 Feb 4-,13121."e010674. doi". 10.1136fiitC-20244)10674. PMID". 39904562; PMCID.. PMC11795382. Ng8n HYS, Seckl MJ, Berkowilz RS, Xiang Y, Goifier F, Sekharan PK, Braga A, Garrtrtt A.Int J Gynaeo)I Obstat. 2025 Sèp,'171 Suppl 1 (Suppl 11.'7&86. th)i'. 10.1002tijgo.70275. Epub 2025 Jul 9. PMID." 40631439. Rimini M. Fornaro L. Ikeda M. Abidoye O. Lucchetb J, Anionuzzo L. Kim JW. Nicheiti F. Saborowski A, Pres5i8ni T, VIv81di C, Rapp05elli IG, Pe8t8rs F. Braconi C, Pin8to DJ, T8rnburini E, Pirch8r C, Tamberi S, Castet F, Verrico M, Pansi A, Coutts N. Chon HJ, Martsrena A, Lamarca A, Landriscina M, Fimkeltneier F, Oneda E, Avallone A. Dell'Aquila E, Perkhofer L. Kim IH. Pinto CMS, Garajova I, Kang B, Corallo S. Fenocchio E. Farinea G. Pastorino A. Diana A. Changhcx)n Y. Schirripa M, Rodriquenz MG, Scartozzi M, Zumstein L. Ghidini M. Prager GW. Aprile G. Spinelli GP. YvnYeh S. Chan S. Waminglon E. Lan¢ianese A. Bekaii-S3ab T. Lavawhi D. Kang M. Lonardi S. Vogel A. Prete AA. Bozzarelli S. Salani F. Persano M, Ma51 G, Balsano R, Niger M, Camera S, Pa55eri L, FerTara M. Satake T, RiTnassa L, Ca5adei-Gardini A. Liver Int. 2025 Dec-,45112).'e71H28. doi.. 10.1111fliv.70428. PMID". 41221651- PMCID.. PMC12606517. ni Cabibbo G, Celsa C, Battaglia S, Enea M. Di Maria G, Grova A, Ciccia R, Manfredi GF, lavarone M, Vogel A, Singal AG, Reig M, Pinato DJ, Camma C. Clin Cancer Res. 2025 Feb 3-31131."543-550. dTh= 10.11581107&0432.CCR-24-2582. PMID.. 39576248.
THE CANCER TREATMENT AND RESEARCH TRUST TRUSTEES REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025 Efficac of atezolizumab Iu5 b8v8CIZUrn8b for unr8sectsbl8 HCC.. S tematic r8view and m8t&8nal real-world evidence Manlredi GF, Fulgenzi CAM, Celsa C, Stefanini B, D'AlessK¥A. Pinter M, Scheiner B, Awosika N, Brunetti L, Lombardi P, Latchlord C, Lee PC. Huang YH. Lin CY. Dalbeni A, Vogel A. Galle PR. Kudo M. Rimassa L, Chon HJ. Cabibbo G. Piscaglia F. Camma C. Pillai A. Pirisi M. Singal AG. Pinalo DJ. JHEP Rep. 2025 22..7181'.101431. doi.. 10.1016fi.jhepr.2025.101431. PMID- 40677696.. PMCID.. PMC12269603. sis of hi Cabibbo G. Celsa C. 8hoori S. Reiberger T. Pinato OJ. Camma C. J Hepatol. 2025 Oec.'83161-.144&1451. oi.. 10.101611 jhep.2025.07.020. Epub 2025 Aug 5. PMID.. 40759204. EAD rrn EDF Garbe C. Amaral T, Peris K. Hauschild A. Arenberger P. Basset-seguin N. Basthott L. Bataille V, Brochez L. Del Marrnol V. Oréno B. Eggermont AMM. Fargnoli MC. Forsea AM. Holler C. Kaufm8nn R. Kelleners- Smeets N, L8llas A, Lebbè C, Leiier U, Lon90 C, Malvehy J, MorenTrRamirez O, Nathan P, Pe118cani G, S8189 P, Stockflelh E, Str81igos AJ, Van Akkooi ACJ, Vièira R. Zalaudek l. Lorigan P, M8ndala M,. Eur J Cancèr. 202S Jan 17,'215. Sacco JJ, Kirk P, Leach E, Shoushtari AN, Carvajal RD, Britton-Rivet C, Khakw S, Collins L, de 18 Cruz- Mèrino L. Eroglu 2. Ikèguchi AP. Nathan P, Hamid O. Butlèr MO. Stanhopè S. R8nadè K, Sato Rèp Mèd. 2025 Apr 15'.6141. Norton B, Sennf811 S, Nortley R, Hill P. Nathan P. lodice V, Zarattr-Lopez N, Carr A. Cureus 2025 Sttp 22.,17 191.. 892896. doi.. 10.77591eurèus.92896. ècollèction 2025 Sèp. PMID.. 41141128. Chee D. Ya Ong CE, Tan DJH. Schal¢enberg JM. loannou GN. Huang DQ.. HCC Policy Study Group. Clin Gaslroenterol Hepatol. 2025 May 12.. S1542-3565125KJ0364-7. doi.. 10.10161 j.cgh.2025.04.014. Epub ahead of prinl. PMID.. 40368132. tsde- tora oni soci Celsa C. Pennisi G. Tulone A. Ciancimino G. Vaccaro M. Infantino G. Di Maria G, Pina¢o DJ. Cabibbo G, Enea M. Mantovani A. Tilg H. Targher G. Camma C. Pell S. Gut. 2025 Apr 7.,74151'.81M24. doi.. 10.11361gutinl-2024-334591. PMID.. 40015951. He alOllular carcinoma in wtth HIV Fulgenzi CAM, Dalla Pria A. Leone AG. Celsa C, Cabibts) G, Scheiner B, Pinter M, D'Alessio A, Zhao Y, Brau N. Bower M. Pinalo DJ. J Hepalol. 2025 Oct'83{41.'971-981. doi.. 10.10161j.jhep.2025.04.028. Epub 2025 Apr 30. PMID.. 40316049. Host-related Deterrninants of Res nse to ImUn0thera in Non- osilion Metabolism Sex and Immune Re ulalion Santo V. Brunetti L. Pecci F. Peroni M. Bamini G. Paoloni F. Buti S. Tiseo M. Riccjuti B. Pinato DJ. Cortellini A. Curr Oncol Rep. 2025 D..271121.'1427-1447. doi. 0.10071s11912-025-01718-7. Epub 2025 Dec 23. PMID.. 41432903,. PMCID.- PMC12743683. Cancer.. Th Inter tsf
THE CANCER TREATMENT AND RESEARCH TRUST TRUSTEES REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025 Immune Check Olnt Inhibitor5 for Patients With Preexistrn Autotmrnune Neurol Fletcher K. Machaalani M. El Hajj Chehade R. Nassaf AH. Nawfal R, Manos M. Menzies AM. Aboubakar-Nana F, Hassel JC. Pinato DJ. Johnson A, Olsson-8rown AC, Carfino MS, Malgeri A. Cortellini A, Singh A, Parikh K. Kim SY. Naqash AR. Long GV. Challa P. Choueiri TK. Sharon E. Shah S. Johnson DB. JAMA Netw Open. 2025 Jun 2..8161'.e2513727. doi.. 10.10011j8manetworkopen.2025.13727. PMID.. 40465294,. PMCID.. PMC12138719.Imrnuno h8no rwi ic Disorder5 Barrichello APC. Elkrief A. Ricciutr B. Ganla T. Marron TU. Wang X. Lotter W. Lindsay J. Santo V, Cortellini A. Sharma B. Felt K. Pf8ff K. L8mberti G. Pecry F. Federico AD. Makarem M. Gandhi MM. Nguyen T. Haradon D, Vaz VR, John50n BE, D8bnath N, Wan9 Y. Kuang AG, Saeed A, R8dford M, Lovly CM, N8bh8n CA, Pinatts DJ, Rodig SJ, Schoenleld AJ, Awad MM, Ie$s1 JV, Naqash AR. Tumor Clin Lung Cancer. 2025 Jun',26141'.288-298.88. doi.. 10.1016fi.cllc.2025.01.014. Epub 2025 Feb 4. PMID.. 40021433. Imm Fulg8nzi CAM, D'Alèssio A, Pinato DJ. JAMA On¢ol. 2025 Fob 1.,11121.'188-189. doi.. 10.10011 jamaoncol.2024.S819. PMID". 39724320. De Martin E. Fulgenzi CAM. Celsa C. Laurent-Bellue A. Torkpour A. Lombardi P. D'Alessio A. Pinato DJ. Gul. 2025 Jun 6.,74171'.1165-1177. doi.. 10.11361guunl-2024-332125. PMID.. 39658265. Pinalo OJ. J Hepatol. 2025 Nov:83151".1232-1233. 10.1016fJ.jhep.2025.07.018. Epub 2025 Sep 5. PMID.. 40914644. Salo T, Butler MO. PipemtrNeumann S. Hassel JC. Nathan P. Shoushtari AN, Rutkowski P, Carvalal RD, Baurain JF, Schlaak M, Piulats JM. Sullivan RJ. Ochsenreither S. Dummer R, Kirkwood JM. Ikeguchi A, Joshua AM. Middlelon MR, Edukulla R. Pfeiffer C. Sacco JJ Clin Canr Res. 2025 Sep 12. doi.. 10.115811078-0432.CCR-25-1513. Online ahead ol print. PMID.. 40938927. Nassar AH, Kim C. Adeyelu T, Bou Farhat E, Abushukair H. Rakaee M. Matteson K, Lau SF, Takabe Y, Ocejo A. Ardeshir-Larijani F. Leal T. Ramalingam S. Alam S, Gray JE. Hicks J. Kaldas D. Baena J. Ber)aga MZ. Nana FA. Grohe C. Leuders H. Citarella F. Cortellini A. Mingo EC. Pancirer D. Das M. Elli5-Caleo TJ. Cheung JM, Lin JJ, Watson AS, Carnidge DR, SridharA, Parikh K. CrovAey F, Marron TU, Aggarwal V, Ahmed M, Sankar K, Kawtharany H, Zhang J, Owen DH, Li M. Nagasaka M, Pinato DJ, Awosika N, Alhamad K. Puri S. Zaman U. Gupla DM. Lau C. Khan H, LiaLM J. Velazquez Al, Brown T, Moliner L, Mosteiro M. R(ha P. Evans M. Vanderwalde A. Elliott A. Nieva J, Lopes G, Ma PC. Borghaei H, Lee M. Young L. Aljumaily R. Mirza H. Kwialkowski DJ. Herbst RS. Flavell RA. Naqash AR. Chiang AC. Nat Commun. 2025 Aug 19,.16111.'7717. doi.. 10.10381s41467-025-63091-O. PMID.. 40830141,. PMCID.. MC12365225. ration of translational research in hase I Is=As stematic review of breast cancer studies in Giannone G, Lombardi P, Filelli M. Paparo J. Rognone C, Stefanizzi S. Valsecchi AA, Zumstein L, McNeish IA, Pinato DJ, Gennari A, Daniele G. Di Maio M. Breast. 2025 JLJn,' 81..104431. doi.. 10.10161 j.brea5t.2025.104431. Epub 2025 Mar 6. PMID." 40132394", PMCID." PMC11984566. of rkm Celsa C, Di Maria G, Lornbardi P, DAessio A. Fulgenzi CAM. Brunetti L, Manfredi GF. Stef8nini B, Spaiacino A, Rigamonb" C, Pirisl M, Lalchford C, Vaccaro M, Enea M, Carntna C, Cabibbo G, Pinato DJ. JAMA Oncol. 2025 Oct 1".11l101".116ll68. (kni.- 10.1001fjamaoncol.2025.2470. PMID." 40810932-, PMCID." PMC12355390.
THE CANCER TREATMENT AND RESEARCH TRUST TRUSTEES REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025 Intem8tional CCA Consensus Consortium. Cholan unmet needs and riorities Banales JM, Rodrigues PM, Affa S, AJ)dersen JB, Aspichuela P, Boulter L, Bridgewater J, Calvisi DF, Cardenas A, Cardinale V, Carpino G. Coulouam C. Dopazo C. Edeline J, Fabris L. Folseraas T, Forner A, Goeppert B. Heikenwalder M. Kendall TJ. Khan SA. Klampen HJ. Koerkamp BG, Lamarca A. Lindsey S. Lleo A. Luedde T. Macias RIR. Moremenl H. Nault JC. Olaizda P. Perugorria MJ. Raggi C. Rimassa L. Saborowski A, Valle JW, Vithayathil M, Vogel A, Braconi C,. N8t R8v Gastroenterol H8patol. 2026 J8n,'23 111'.65-96. doi.. 10.10381s4157M25-0115&w. Epub 2025 Dec 10. PMID.. 41372578. iOGqrianoma 2026.. ststus uo Galle PR. Reck M. Pinato DJ. Garcia-campelo R. Finn RS. Cousin S. Zanghi J. Bemaards CA. Swanson SJ, Morris S, Song Y, Peters S. Cancer Treal Rev. 2025 Nov.. 140..103016. doi.. 10.10161j.ctrv.2025.103016. Epub 2025 Au9 25. PMID.. 40886486. Lombardi P. Kim JS. Manfredi GF. Celsa C, Fulgenzi CAM. O'Alessio A. Stef8nini B. Doshi NC. Warmiroton E, M8rron TU, Pinter M, Scheiner B, Kang B, Lim HY, Hsu WF, Wietham B, Silletta M, Parisi A, Lin CY. Dalb8ni A, Masi G, Schanl8in M, von Felden J, Pisca91ia F, Galle PR, Kudo M. Pressi8ni T, Rimassa L, Pirisi M, Cabibbo G, Chon HJ. Pinato DJ. JHEP Rep. 2025 Sèp 23",71121.'101S95. doi.. 10.10161 j.jh6pr.2025.101595. PMIO." 41321927.. PMCID.. PMC12657762. Cortellini A, Garbo E, La Cav8 G, Ciiar8lla F, Santo V, Brun8tti L, Pinalo DJ, Nèidoo J, Loza M, Gonova C, Getlinger S. Kim SY. Jayakrishnan R. Zarif TE. Russano M. Peca F. Di Fed&rico A. Montrone M, Owen DH. Signorelli D. Li M, Camerini A. Halmos B, Vincenzi B, Metro G. Yendamuri S, Grossi F. Josephides E, Tomasik B. Giusti R, Bria E. Sebastian M. Rost M. Acker F, Landi L. Mazzoni F. Morabito A, Leonetti A. Cantini L, Mountzios G, Kalvapudi S. O'Reilly D. Karapanagiolou E. Monnel I, 88en8 J. Macerelli M. Majern M, Piedra A, Cortinovis DL, Tonini G, Minuti G, Mezquiia L, Go)rria T. Beninato T, Lo Russo G, Prel8J A, De Giglits A, Bièllo F, Nana FA, Dingamans AC, Aèrts JG, Fèrnara R, Abu Hejlèh T, T8kad8 K, Naq8sh AR. Garassino MC, Wakèlè& HA. Nassar A. Ricciuti B, Soda P. Canjso CM, Guarrasi V. Lung Cancer. 2025 Nov., 209-.108799. doi.. 0.1016fi.lungcan.2025.108799. Epub 2025 Oct 16. PMID.. 41108882. Swift BE, Cooprnans L, Singh K, Coyl• C. Wilkès EH, Jabbar l. Mahèr G, Aguiar X, Salman L, Palmèr JE, Sarwar N, Caldwell R, Ghorani E, Kaur B, van Trommel NE. Lok CAR. Winter M, Seckl MJ.BMJ Med. 2025 Apr 23..4111'. e001017. doi.. 10.11361bmjmed-2024-001017. ecollection 2025 Jan.PMID'. 40309224. Joyce CM, Maher GJ, Dineen S, Suraweera N, Mccarthy TV, Coulter J, O'Donoghue K, Seckl MJ, Fitzgerald 8.J Clin Pathol. 2025 Apr 17,'78151'.327-334. doi.. 10.1136ficp-202&209269.PMID". 38555105. Ascierto PA, Del Vecchio M. Merelli B. Gogas H, Arance AM. Dalle S. Cowey CL. Schenker M, Gaudy- Marqueste C, Pigozzo J. Marquez-Rtxlas l. BuU8r MO, Di Giacomo AM, Gligich O, De La Cruz-merino L, Arenberger P, Atkinson V, Nathan P, Hill A, Millwai¢J M, Fecher LA, Khushalani Nl, Queirolo P, Soomro R, Rathod D. Askelson M, Pe Benilo M. Joseph D. Larkin J. N Engl J Med. 2025 Oct 18. doi.. 10.10561 NEJMoa2504966. Online ahead of prinl. PMID.. 41124198. r liv Pinato DJ. J Hepatol. 2025 Jul",8311}."27&274. d". 10.1016tI.jh8p.2025.03.025. Epub 2025 Apr 25. PMID.. 40287289. Pin8lo DJ. J Hepatol. 2026 J8n;84{11'.233-234. doi.. 10.1016fi.jhep.2025.11.001. Epub 2025 Nov 20. PMID.. 41271523.
THE CANCER TREATMENT AND RESEARCH TRUST TRUSTEES REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025 Phase I dos8-escAlation and harm8CA)d advanced so11d tumors Luke JJ, Pinato DJ, Juric D, LoRusso P, Hosein PJ. Desai AM, Haddad R, de Miguel M, Cervantes A, lfjm WS, Marabelle A, Zhang Y, Rong Y. Yuan X. Champiat S. J Immunother canr. 2025 Feb 20.'13121'.e010511. doi.. 10.1136fiitc-2024-010511. PMID.. 39979069.. PMCID.. PMC11842995. amic stud of STING onist E7766 in TD Lok C. van Trommel N. Br8icu El, Planchamp F, Berkovmtz R. Seckl M.. EOTTD-ESGO-GCIG-ISSTD Guid81ine Committe8.J Clin OrKol. 2025 Jun 20..431181'.2119-2128. doi.. 10.121JOIJCO-24-02326. Epub 2025 May 13. PMID." 40359461. Scheiner B, Lornbardi P, D'Alessio A, Kirn G, Talawoghi M, Petrenko O, Goldin RD, Fulgenzi CAM. TorkpourA, Balcar L, Maun FA, Pornej K, Hirnmelsbach V, Barsch M. Celsa C. Cabibbo G, Cheon J. Krall A. Huckè F. Di Tommaso L. Bemasconi M, Rimassa L, Samson A, Stelanini B. Mozayani B. Trauner M, Lackner C. Stauber R. Vasuri F. Piscaglia F. Bengsch B. Finkelmeier F. Peck.Radosavljevic M. Rasmussen Busund LT. Marafioti T. R8hbari M. Heikenwalder M. Pinter M. Chon HJ. Rakaee M. Pinalo DJ J Immunolher C8n¢•r. 2025 Od 5..131101.'eO10975. doi- 10.1136fiil¢-2024-010975. PMID.. 41052888; PMCID.. PMC12506175. Takada K, Shimokawa M, Cortellini A. Pinato DJ. Mizuki F. Tak8mori S. Lung Cancer. 2025 Nov,. 209..108787. doi.. 10.10161j.lungcan.2025.108787. Epub 2025 O¢t 10. PMID.. 41105995. Amarnath Challapalli. Pranlik Das. Anand Shamia. Rajanee Bhana. Alison Jane Birtle. Dakshinrnoorthy Muthukumar. Manreel Randhawa. Sanlhanam Sund8r. Mark Prentice. Diletts Bianchini, Emily Renninson. Mi9uel Capomir, 1s8bel Syndikus. K8malr8m Thippu Jayapiakash, Thiraviyam Elumalai, Sarah G¢)o(Jwin, Omi Parikh, Paul While, Emily Foulston•. Joumal of Clinical Oncol(MJy 2025 43..5 suppl, 89-89. Shah H. Phillips J, Dhanjal MK. Dassan P, Seckl M. Frise C.Ob5tet Med. 2025 Jul 4..1753495X251354997. doi.. 10.117711753495x251354997. Online ah88d of prinl. PMID.. 4062106. Re roducible safe and effica of durvalumab without tremelimumab for he atocellular carcinoma Celsa C. Pressiani T. Nishida N. Chamseddine SM. knind A. Li M. Fortuny M. Khaled NB, lavarone M. Toy¢)da H. Rapposelli IG. Casadei-Gardirbi A. Wivaldi C. Ulahannan S. Andanamala H. Scheiner B. Pinter M. Orfandi E, Fulgenzi CAM, Manfredi GF, Li)mbardi P, D'AleS5 A, Stefanini B, Villani R, Ponzi8ni FR, Stella L, Caminats O, Rica AD, Gonzalez M, SraCin0 A, Di Maria G, Vaccaro M, Cabibbo G, Carnma C, Reig M. Kelley RK, Singal AG, Kaseb AO. Kudo M. Rimassa L. Pinato DJ. JHEP Rep. 2025 Nov 0'.8131.'101685. doi.. 10.10161j.jhepr.2025.101685. PMID.. 41675370.. PMCID.. MC12886069. rwv I With Imm and Histol Sub es Clin Genitourin Cancer. Bakaloudi DR, Talukder R, Enrighl T, Leary JB, Makrakis D, Diamantopoulos LN, Hobeika C, Thomas VM, Swami U. Zakopoulou R. Bamias A. Brown JR. Pinato DJ, Latchford C, Jindal T, Koshkin VS. MurgiAt J. mile11 M. Frobe A. Johnson J. Zakharia Y. Mva A. Nguyen CB, Hui G. Drakaki A. RodrigLJez-Vida A. Rey-cardenas M, Castellano D. Buznego LA, Duran l. Barrera RM. M8rmolejo D, McKay RR, Stewart TF, Barata P, Epstein IB, Bellmunt J, Yu EY, Raychaudhuri R, Nadal R, Vakar-Lopez F, Gupta S, Wright JL, Khaki AR, Grivas P. 2025 Aug',23141.'102356. doi.. 10.101WI.dgc.2025.102356. Epub 2025 Apr 14. PMID.. 40378559. With
THE CANCER TREATMENT AND RESEARCH TRUST TRUSTEES REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025 Retros ectiv8 multic&nter 8n81 rnetastatic uveal melanoma Ciemik A, Ciernik L, Bonczkowtz P, Morak M, Heinzeding L, Bennaceur Y, Lavless A, Sullivan R, Kott J, Gebhardt C, Carter TJ, Nathan P. Tschopp S. Dummer R, Ramelyte E. Oncologist. 2025 Jul 4., 30 171'.oya1173. doi.. 10.10931oncololoyaf173. is of realIfe toxi and outcome of i ilimum8b 8nd nivolumab in Safet and 8fficac of irnrnun8 check int thera for th8 tr88tm8nt of ati8nts with Gqrdiac m8t85t8SiS'. Nassar AH. Abou Maiwi S, El Zarif T. Denu R. Macaron W. Abdekwahab N, Freeman D. Vasbinder A, Hayeck S. Anderson E, Goodman RS. Johnson DB. Grynberg S. Shapira R. Kwan JM. Woodlord R. Long GV. Haykal T. Dent S. Kojima Y. Yonemor K. Tandon A. TVIn0 A. Akhter N. Yang EH. Hui G. Drakaki A. El- Am E, Kozaily E. Al-Hader A Bou Farhat E. Babu P. Mittra A. Li M. Jones N. Baena J. Juarez Herrer8 M. Foder8ro S, Nana FA, Kim C, Sackstein P, Pankh K. Desai AP, Smith C, Cort8llini A, Pinato OJ, Korobwicz J, Lopetegui-Lia N, Funchain P, Chtsudhary A. Asnani A, Navani V, Meyers D, Stukalin I, Oceio Gallegos JA, Trent J, Nusral S, Malvar C, McKay RR, Neilan TG, Chou8iri TK, Naqash AR. J Immunoth&r Cancer. 2025 Mar 3..13131'.e009364. doi. 10 11361jitc-2024-009364. PMID.. 40032601.. PMCID. PMC11877189 ni Qas P, Sharma A.th1Oba R.A.A,Jknlo J. YthumL3Sl320 September 2025. in h Salia H, Wi5cher L. D'Ales5io A, Godbole I, Suo Y. OttTrMora P. Beck J, Neum8nn O. StÈnzing*rA, Schirmachbr P, Fulgènzi CAM, 81aum6is8rA. 808rriès M, Roehlen N, SchulthèiAY M, Hofmann M. Thimmè R. Pinalo DJ, Longerich T. Bèngsch B. Gut. 2025 Fab 6,"74131'.451-466. doi." 10.11361gutjnl-2024-332837. PMID.. 39349005,. PMCID.. PMC11874287. Sehreèdar B, Pr8sad P, Gb8d6gèsin O, Gupla S. Ffazèr R, Hèanèy S, Franks H. Blair C, Stutt8rd M, Badow C, Cook H, Winter H. d'Anenzo P. Symington J, Radrf Y. Rampes S, Nathan P. Young K, Shaw H, Carr A. Willis M. Cancers (Basell. 2025 Dec 9:171241'.3935. doi.. 10.33901cancers17243935. HIV Fulgenzi CAM, Dalla Pria A, Leon&AG, Martinez M, Del Peral EFM. Fk)res ME. Bower M. Pinato DJ. BMC Cancer. 2025 Jul 1'.25111'.1104. doi." 10.11861s12885-025-14326-2. PMID.. 405969)9; PMCID.. PMC1221W1. Comanici M, Robertus JL, Rice A, Nathan P, Anikin V Melanoma Res. 2026 Feb 1,36111..70-74. doi.. 10.10971CMR.00(x)O0[jOolo66. Ewb 2025 Oct 17. PMID: 41097815. Martirena A, Lombardi P. Pinato DJ, Rimaw L. Larnarca A. ESMO Gastrointest Onool. 2025 Fgb 17.,7..100139. doi." 10.1016fJ.8smogo.2025.100139. PMID". 41646488," PMCID.. PMC12836512. S stemic treatment in atients with he tocellular carcinoma and advanced liver d function Pinter M. Fulgenzi CAM. Pinato DJ. Scheiner B. Gul. 2025 Jun 6.'74171=1178-1188. d.. 10.11361 gutjnl-2025-334928. PMID.. 40301119. Tertia I m hold structurè d ami(s at Ihè centre of immunother nse in he atocellular carcinoma Pinalo DJ. J Hepatol. 2025 Apr.,82141..7677O. doi." 10.1016fJ.Ihep.2024.12.040. Epub 2025 Jan 21. PMID.. 39843298.
THE CANCER TREATMENT AND RESEARCH TRUST TRUSTEES REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025 Th8 2024 ILTS-ILCA cons8nsu5 reCMMendatiOnS for liver trans cholan iocarcinoma Kodali S, Kulik L, D'AJlessio A, De Martin E, Hakeem AR. Lewnska M, Lindsey S, Liu K, Maravic Z, Patel MS, Pinalo D, Rammohan A, Rich N, SandLttZi ZaMpalI1 M, Victor DW 3rd, Vinaxia C, Brombosz EW, Villanueva A. Meyer T. Selzner N. Ghobrial RM, Rela M. SapiscKhin G.. and the ILTS ILCA Consensus 2024 Group Liv8r Transpl. 2025 Jun 1..31161'.81&831. doi.. 10.10971LVT.IM)00000000000589. Epub 2025 F8b 28. PMID.. 40014003. ant8tion for HCC and intrahe 8tic Cabibbo G. Fkn'massa L. Lamar¢a A. hAasi G. Daniele B. Pinato DJ. Casadei-Gardini A. Cancer Treat Rev. 2025 Jun',137..102955 doi.. 10.1016fi.ctrv.2025.102955. Epub 2025 May 9 PMID.. 40373702. Ng K. Ganguli S. Rajan P. Sharma A. Shamash J. Joumal ol Clinical Oncology 2025 43'.5_suppl. 644.644. TIM INT inin PAwith IMT EBPA i Plummèr R. Sodergren MH, Hodgson R. Ryan BM. Rèull N. Nicholls JP, Reebye V. Voutila J. SinKJaglia L. Meyer T. Pinato DJ. Sarker D. Basu B. Blagden S. Cook N. Jeffrey Evans TR, Yachnin J. Chee CE. Li D. El-Khoueiry A. Diab M. Huang KW. Pai M. Spalding D, T81bol T. Noel MS, Keenan B. Mahalingam D, Song MS. Gros50 M, Amaud D. Augusle A, Zacharoulis D. Storkholm J, M¢Neish l. Habib R, R05si JJ. H8bib NA. Cèll R8p Mad. 2025 Apr 15.,6141.'102041. dtsi.. 0.1016fi.xem1.2025.102041. Epub 2025 Mar 31. PMID.. 40168999,. PMCID.. PMC12047497. Cortellini A, S8nlo V, Brunetti L, Garbo E, Pinalo DJ, L4 Cava G, Naidoo J, Katz A. Loza M. Ng81 JW. GÈnov8 C. Gèth'ngèr S, Kim SY, Jay8krishn8n R. El Zaril T, Russano M, Pacci F, Di F8d6ricts A, Alèssi JV. Montrone M, Owen DH, Ramella S, Signor&lli D. Fidltsr MJ. Li M. Camerini A, Halmos B, Vincenzi B, Metro G, Passiglia F, Yendamuri S. Guida A, Ghidini M. D'Alessio A. Banna GL. Fulgenzi CAM, Grisanti S. Grossi F. O'lncecco A. Josephides E. Van Hemelrijck M. Russo A. Gelibter A, Spinelli G, Verrico M. Tomasik B. Giusli R. 8alachandr8n K. Bria E. Sebastian M. Rosl M. Forster M. Mukheriee U. Landi L. Mazzoni F, Avjayeb A, Dupont M, Curi<)ni- onlewlrg A, Chiari R. Sforza v, fiseo M, Friedlaender A, Addeo A, Zor8tt9 F, De Tursi M, Cantini L, Roca E, Mountzios G, Rocco D. Dèlla Gravara L. Kalvapudi S, Innts A, Bironzo P, Di Marco Barros R, O'Reilly D. Fitzpalrick O. Karapanagiotou E. Monnet I, Baena J, Macerelli M, Piedra A, Agustoni F, Cortinovis OL, Tonini G. Minuti G. Bennati C. Mezquita L, GorrAa T. Servetto A, Beninato T, Lo Russo G. Prelaj A. De Giglio A. Rogado J. Moliner L. Nadal E. Biello F. Nana FA. Dingernans AM. Aerts JGJV. Ferrara R. Abu Hejleh T. T8kada K. Naqash AR. G8ra5sino MC. Pe¢ers S. Wakelee HA. Nas5ar AH. RicciLJti B, Sod8 P, Caruso CM, Guarrasi V. J Iwnmunoth8r Caneer. 2025 Sep 29",13191'.e012423. doi". 10.1136tjitc-2o2l2423. PMID.. 41022528; PMCID.. PMC12481261. rn Abdul Aziz N, Masangwi DD, GarvJuli S, Sh8wTha A. Ng K, Rajan P. Sham8sh J. Th8rAdv M8d Oncol. 2025 Aug 30. Craddock C. Earwaker P. Fittall M. Fontana E. Ganesh D. Gerlinger M. GhafiK)r Q, Jones RP, Kunene V, Lee L, Lee R, Lee SM, Linch M, Little M, Liu J, mcKene H, Petty R, Pinato DJ, P0e5 T, Protheroe A, Robin50n T, Ross PJ, Shiu KK, Spicer J, Symeonid6s S, rilby M, Vimalachandran D, Wang JY. Wardley A. Winter H. Camb Prism pc1S Med. 2025 Jan 20',3.'e1. doi.. 10.10171pcm.2024.5. PMID= 39944656". PMCID.. PMC11811843. 10-
THE CANCER TREATMENT AND RESEARCH TRUST TRUSTEES REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025 UK wei ht and w811n8ss r85earch consorburn. Im cl of GLP-1 rec8 tora onist-induced wei hl loss on 22 cancers In the nexi ten ears usin Markov state-transition model - A UK wei ht and wellness cancer landsca e anal sis Dong J, Starkey T, Cheng VWT. Clark J, Pinato DJ, Robinson T, filby M. Tumbull CD. Yw Lee L.. Cancer Epidemiol. 2025 Aug.. 97.'102837. doi.. lo.101l.C8nep.2025.lO2837_ Epub 2025 May 24_ PMID.. 40413897_ Carter TJ. Broadloot J, Coupland SE, Damalo 8. Evans H. Fenwck S, Khoia L, Krausa T, Lewis R, Nathan P. Modi S. Negretti G. Rashid S. Sacco JJ. Shaw H. Sisley K. Sowton R, Turajlic S. Turnbull N. Woraker A. Wheater M. Eur J Cancer. 2025 Oct 1.. 228..115687. doi.. 10.1016fi.eJca.2025.115687. Epub 2025 Aug S. PMID.. 40885127. Flnanclal r•vl•w The finan81 result5 for the year are as shown in th8 financial Section of his report and ¢over acwunting period of 12 months frorn 01 January 2025 10 31st December 2025. The carry fOard funds as at 31st December 2025 amount8d to £1,639,194, of which £1,28S,843 was unrestricted and £353,551 was restrfcted. Total income lor the year was £325.771 12024.. £502.1511. derived primarily from donations and investment income. Total expenditure was £283,83112024 £142,202), rnainly relabng ¢0 SearCh granls and sUPPOrt costs. Th$ tru$lsg$ consid&r th& ¢harily to be a going COnM. with $uffio$nt to m$*t obligations lor at1g8$1 the n8xl 12 months. Plans for future p•rlods Inv•8tlng In fundral8lng Following her temporary appointment in 2025. Mrs Frankie Britten has been offered a pemanent position as Fundraising Manager, commencing in 2026. This will allow the charity to place greater focus on fundraising and income generation, while enabling Mrs Laura Brown lo concentrate on stralegic and operatsonal matters. Plan$ for r•$oareh CTRT will continu6 lo support a divarsè variaty of f8s&arch into many cancars including $8vèral diffarant typas of less common cancers such as ovarian. ulenne. melanoma and also very rare cancers such as gestationa trophoblastic disease IGTOI. germ cell lumours and rare gynaecological cancers. Our research supports clinical studie5 as well as laboratory locused work such as developing novel biomarkers. lrnmunotherapy continues to be a major area of interest in ¢he cancer worfd and CTRT SUPkX)rts research studying the effects of immun(therapy in trophoblastie, lung and wnal eancèrs. CTRT are currently trying to deveh)p ways to avoid the use of toxic multi4rug chemotherapy to treat GTD by running a trial of imrnunotherapy treatmenl. This lrial is a major fundraising focus for CTRT in 2026. 11
THE CANCER TREATMENT AND RESEARCH TRUST TRUSTEES REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025 RISK MANAGEMENT The Trustees are aware of the risk5 affecting the Twst and its work and have ensured that polici are in p18ce to mitigate the effect ol these risks. Flnanclal rl$ks and Inveglment A key aim of the Board is to ensure CTRT holds adequate reserv85 for working caprtal purposes and has sufficient fLJnds to rneet contractual li8biliti85 and wnding dovm costs, if the organisats'on were to cJos8. Thi5 includes redundancy pay, amounts due to creditors and commitments under contracts. CTRT'S level of reserves also helps the organisation lo plan expenditure against variations in the way funding is received. To balance tt)e uncertainly of funding, our policy is to maintain financial ServeS to cover these costs and allow lor an orderly wind down. The current estimate of these costs is c £65.000. Without cuent level of support from our individual donors and based on current expenditure levels. CTRT is estimated to still remain in a position to cover these c05t5 for the corning 12 months As our unr8strict8d rèservès st8nd at abotjt £1.2m. Govèrnanco strudu The review of governance structure. pdicies and procedures was commen&ed and following that review. any recommendations rnade and agreed upon by Ihe Iwstees will b8 implemenieLI in Ihe authorised order. StTu¢tur•* gov¥rn•n¢g ond rn•n•9em¥nt The trustees who served during the year and up to th8 date of SnatUre ofthe financAal ststements were.. Mr Russell Hallam Dr Paul Nathan Dr A Sharma Dr David Pin810 Prol. Michael Seckl Prol. Gordon Rustin Ms Kirandèèp Grèwal Dr Ehsan Ghorani Mr Glèn Williams Professor Marcia Hall (Appointed 17 May 20261 (Retiremenl 31 July 20251 RESERVES POLICY The Iruslees. policy is ¢0 maintain Sufflent reserves io cover WJ years of the charity's operabng costs. together wilh the funding required ¢0 meet exisling research cornrnilments. This is intended to provide financi81 stability in the ewnt ol 8 r9duction in don8tion$ and $nsurs thal th$ ¢harity ¢an Continuo to m1 its oblKJatK)ns. Annual operating costs are currently estimated at approximately E65,000, giwng a minimum operats'ng reserve requirement of £130,000, in addition to amounts requi lor committed searCh projects. At 31 December 2025, the charity held unre5tricled lund5 of £1,285,643, of which £1,221,038 repr8sent8d fre8 reserves. Thi5 cornpares with the tru5tees' minimum operating reserve requirement of £130,000, together with those funds required to meet existsng resèarch commrtmènts. The trustees consider the level of serveS held to be appropriate. laking into acwunl the charivs funding commitments. ¢he uncertainty of fuiure donation income and its plans to continue supporting research projects. Due lo the tirning of fundraising income and expendrture on charitatAe activitie5, the charity can hold significant cash balances ahead ol planned eXpendrtu. The trustees have therefo placed a proportion of these funds into interesl-bearing deposit accounts. induding tice accounls. whilsl maintaining sufficienl accessible funds to meet the charity's ongoing commitments. 12-
THE CANCER TREATMENT AND RESEARCH TRUST TRUSTEES REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025 CONCLUSION Research. either totally or partly funded by CTRT leil to 73 publicab.ons in 2025. The Trustees are confident that CTRT will o)ntinue lo fvnd work Ihat will lead to improvements in the detection, monitoring and treatment of cancer and care for palients with cancer. The trustees r port Was approved by the Board olTruslees. Prol. Michael Seckl Truslg9¥ Dalè,. 28/10/2026 13-
THE CANCER TREATMENT AND RESEARCH TRUST STATEMENT OF TRUSTEES RESPONSIBILITIES FOR THE YEAR ENDED 31 DECEMBER 2025 The trust8es are r8Stx)nsibl8 for pr8paring the Trustees R8POrt and the finana81 stat8rn8nts in 8ccordanc8 With applicable law and United K"bngdom Accounting Standards Iunited Kingdom Generally Accepted Accounlin9 Practice). The law applicable to charities in England and Wales requires the Injstees to prepare financial slatements for each fin8n¢ial year which give a tnje and fair view of the stale of affairs of Ihe charity and of the incoming resources and application of resources of the charity for thal year. In prepanng these financial ststements. the trustees are required to". select suitable accounting poliaes and then apply them consistently., - observe the rnethods and principles in the Charities SORP.. make judgements and estimates that are reasonable and prudent- state whether applicable awounting Standards have been followed, subject to any material departures disc105ed 8nd explained in the financial statem8nls", and prepare the linanaal slalemenls on the going concem basis unless it is Inappropriatè lo presun that the charlty will continue in operats'on. The trustees are responsible lor keeping sufficient accounbng records thal disdose r88sonable accuracy at any lime the financial position of the charity and enable them lo ensure that Ihe financi81 statements cornply with the Charities A¢t 2011. th$ Charily IAc¢ounts and Reports) Regulations 2008 and the provisi(>ns of th& irust deed. Thtry arè also rsponsibl6 lor safeguarding thè assets ol l+)è chanty aThJ hèncè lor takin9 rèasonablè stops lor thè prevention and detection ol fraud and olh6r irregularities. 14-
THE CANCER TREATMENT AND RESEARCH TRUST INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF THE CANCER TREATMENT AND RESEARCH TRUST I r8POrt to the trust8es on rny ex8mination of th8 finana81 statements of The Cancer Tr8atm8nt and Research Trust Ithe charity) for the year ended 31 December 2025. Responslbllltles and basls of report As the charity'5 tru5t8es you are r8SW)n5ibl8 for thg preparation of the 8cwunts in a)rdn¢9 with the requirements of the Charities Act 2011 1.the Act'i. I report in respect of my examinats'on of the charily s accounts carried out under section 145 01 the Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 14515Xbl of the A¢t. Ind•p•ndènt •xamlnèr's stat•m•nt Since the charity's gross income exceeded £250.000 your examiner must be a member of a body listed in section 145 01 th8 Act. I confirm th8¢ l arn qualified ¢0 undertake the examina¢ion bu8 l am a rnember of ACCA, which 15 on& ol the listèd bodiès. I have completed my examination. I confimi thal no matters have rThne to my attention In CLnnection with the examination giving me cause to believe that in any material resp8cl'. accounting racords were not kèpt in respect ol the d)arity as requirad by s8Ction 130 of lh& Charltlas Act 2011. the financial ststements do not accord with those records., or the accounts do not comply with the applicabl8 requirements concerning the lorni and content of aco)unts set out in the Charities (Accounts and Reporlsl Regulations 2008 other than any requirernenl that the accounts give a 'true and fair view, which is not a matter considered as part of an independent ex8rnin8tion. I have no wneèms and havè ¢om¢ across no othr matters in nn¢t1¢) wrth lh& examination to which 8tt8ntion shotild be dr?wn In thls ort in ordgr to ènabts a wopgr und8tstandin9 01 thé financlal statémènts to ba ra8ch¥d. Adam Shelley FCCA Sobell Rhodes LLP The Kineti¢ C¥ntr* Theobald Street Elstrèa B0hamwood Hertfordshire WD6 4PJ United Kingdom Dated.. 29/10/2026 15-
THE CANCER TREATMENT AND RESEARCH TRUST STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOMEAND EXPENDITUREACCOUNT) FOR THE YEAR ENDED 31 DECEMBER 2025 Unr•strl¢ted R•strl¢ted funds funds 2025 2025 Total Unrèstrlcted R•strlcted funds funds 2024 2024 Total 2025 2024 Notes Income from: Donation and legacies Inv8Stmenl 289.876 24,880 11,015 300,891 24,860 384.379 17.590 100,182 484.561 17.590 Total Income 314,756 11,015 325,771 401.969 100.182 502.151 Expendltur• on.. Raising funds Charitable activities Othèr èxpenditure 7,643 4.960 63.708 7,643 212.480 63,708 5,108 4.835 51.323 5,108 85.771 51.323 207.520 80.936 Total •xp•ndllur• 76.311 207.520 283,831 61.266 80,936 142.202 Nel gain$ on Investments 51.834 51,834 Nét Incom•l1•xnd1IUr•l 290,279 1196,$05) 93.774 340,703 19,246 359,949 Transfers behyeen funds 1208,814) 208.814 136.4471 36.447 Met movem•nt In fundi 81,465 12.309 93,774 304,256 5S.693 359,949 R•conclllatlon of funds: Fund balances at 1 January 2025 1.204,178 341,242 1.545,420 899,922 285,549 1,185,471 Fund balanc•s at 31 December 2025 1,285.643 353.551 1.639.194 1.204.178 341.242 1,545.420 The statement of financial ac1MS indudes all gains and losses reo)gnised in the year. All income and expenditure derive frorn conts'nuing activities. 16-
THE CANCER TREATMENT AND RESEARCH TRUST BALANCE SHEET AS AT 31 DECEMBER 2025 2025 2024 Notes Fixed assets Intangible assets Tangible assets Investments 11 12 13 5.289 1.013 58,303 1.505 1.494 6,469 64,605 9,468 Current assets Debtors Investments Cash at bank and in hand 14 15 32.797 765,979 848.842 10,274 1.591.696 1.647.618 1.601,970 Cmdltors.. amounts lalllng du• thIn one year 16 173.0291 166,0181 Not curr•nt a8Bets 1.574.569 1.535,952 Total •s¥•ts l•s¥ ¢urr•nt Il•bllltl¥s 1.639,194 1.545,420 Tho fund¥ of th¥ chaTIty Restricted income funds Unrèstrictèd funds 17 353.551 1.285,643 341.242 1,204,178 1,639,194 1,54S,420 Thè Ilnanclal statements w8r8 approv8d by thè tru$tèg$ on. 28/10/2026 Prof. Michael Seckl Trust••s 17-
THE CANCER TREATMENT AND RESEARCH TRUST NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 Accounting policies Charfty Infomiatlon The Cancer Treatment and Research Twst is a exists to support treatment and research into many forrn5 of malignant dis8as8 and has b8en particularfy Involv8d in UndetandIng how certain cancer5 d8velop, finding better ways to monitor them and develtsping new anli-cancer agents. 11 remains committed to funding research that is not adequately lun¢Jed eilher by the major cancer charits.es such as CRUK, the MRC of the phamiaceutical industry. 1.1 Ac¢ountlng convontlon The financial slalemenls have been prepa in accordance wth the charivs goveming document, the Charities Act 2011. FRS 102 Yhe Financial Reporting Standard appliCae in the UK and Republic of Ireland" I'FRS 102.1 and the Chanties SORP "Accounting and Reporting by Charities.. Slalernent ol Rewmmen(Jed Practice 8pplicable to Charities preparing their accounts in accordanc8 With the Fin8nci81 Rèporting Standard applicablè in Ihè UK and Rèpublic ol Irèland IFRS 1021. (èffective 1 January 20191. Thè charity is a Public Benefit Entity as dèfined by FRS 102. The charity has taken advantage of the provisions in the SORP for charities not to prepare a Statent of Cash Flows. Thè finan¢ial ststem*nts havo d¢partod from Chaniie$ IA¢¢ounts and Rèports) Règulations 2008 tsnly to th& èxtant rUired to providè a true an¢J lair vièw. This dèparturè has involv•d following thè Statamènl of Recommended Practice for chanties applying FRS 102 ralher Ihan the version ol the Statement of Recommended Practice which is relerred to in the Regulations bul which has since been withdrawn. The financial st8lemenls are prepared in slerfing, which 15 Ihe functitinal currency of tho charity. Monetary amounts in these financial Ststgments ar¢ tg Ihg nearg$t £ 1. The financial statements have be•n pr8par8d und8f tha historfcal cost convention. The princlpol occountlng policies adopted are set out below. 1.2 Golng concern At the time of approwng the finanaal ststements. th& Injslees have a reasonable expectation that the charity has adequate resources lo continue in operational existence for the foreseeable lulure. Thus the trustees continue lo adopt the going concern basis ol accounting in preparing Ihe financial slalernents, 1.3 InGom• All Incorne 15 recognistsd in thè Statèmènt of Financial Actiti5 onc• thè charity has 8ntitl6m•nt to thè funds. it is probable that the income 11 be received and lh& amount can be measured reliably. Donations and legac4es are prowded lo the Charity. in order thal the Chanty can fuffil its purpose. L•gacles Legacy income is recognised ¥then receipt is probable. Ihe amount can be measured reliably. and notification has been ceiVed from the personal representatives thal Ihe estste acixjunts have been finalised or that distributions can be reli8bly measureil. Grant income Grant income that is subject to perform8nc8 (xjndthons is retXYJniS8d when the charity has 8ntiUem8nt to th8 funds, it is probable that Income will be received and any performance condition5 have been rnet. Grants thout performance conditions are recognised when the charity becomes unconditionally entitled to the income. 18-
THE CANCER TREATMENT AND RESEARCH TRUST NOTES TO THE FINANCIAL STATEMENTS {CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025 Aeeounting pollelès IContlnu•d) Donated goods, Services and facilities Where donated g(x)ds or Services meet the recognition criteria of the SORP, the income 15 recognised at the lair value of the gotKls or s8Nic8s receiv8d. Where it is not practicable to reliably m8asur8 the vJue, th income is nol recognised, but Ihe nature ol the donation is disdose(l in the trustees, report. 1.4 Expenditure Liabilities are recognised as expenditure as swn as there is a legal or constructive obligation committing the charity to that expenditure, it is probabl8 thal a Iransfer of economic beneffts will be required in settlement and the amount ol the obligation carb rneasureil reliably. Expenditure is accounted for on an accruals basis and has been dassified under headings that aggregate all cost related to the category. whe costs cannol be direcuy attributed lo partiwlar headings they have been allocated to activ.e5 on a basis consistenl with the use of resources. Governance and support costs Support costs are those functions thal assist the work of the charity but do not direcfjy undertake charitable activities. These include administrative and financi81 man8gernenl cosis. Where 5UPPOrt costs cannot be directly attributed, they are apportioned to 8divilies based on an estimate of stalf time or another suitable basls. Govemance costs are the costs associated with statutory compliance and oversight of the charity, induding independent examination lees. accounts preparation costs and trustee meeling expenses. Governanc? ¢r)$ts artr present as a separate ¢omwrwit of eXnd11yre in th¥ Ststemtrnl of Flnan¢lal Activities. 1.5 Intonglblg Ilxod 0¥ty9ts oth•r than goodwlll Amortisation is recognised so as to write off the cosl or valualTh ol assets less their residual values over their U8elLJI lives on the following bases.. Websile 10% on reducing balance 1.6 Tanglbl• flx•d a8S•ts Depreciation is recognised so as to writg off the $t or valuation o18s$0ts le$$ their widual valutrs over their useful lives on the fdlowing basès.. P18nt and equiprnenl Cornpulers 25% on reduung balanee 33% on ¢ing balance 1.7 Flxed asset Investments Lisled inv85tments are inits'ally recognised at cosl 8nd subsequ8nUy m8a5ured at fair value 8t the b818nc8 sheet date, based on quoted rnaet prices. Changes in fair value are recognised as gains or losses on investments in the Statement of Finanaal Aclmbes. Investment income is recognised when receivable. 1.8 Cash and cash equivalents Cash and cash equivalents include cash in hand. deposits held at call vAth banks. olher 5hort-term liquid inv8Stments wth original maturities of three rnonths or 18SS, 8nd bank overdr8fts. B8nk overdrafts ar8 shown thin borrowings in current Iiabilitie5. 19-
THE CANCER TREATMENT AND RESEARCH TRUST NOTES TO THE FINANCIAL STATEMENTS {CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025 Aeeounting pollelès IContlnu•d) 1.9 Financial instruments The chanty has elected to apply the provisions of sect 11 'Basic Financial Instruments, and Section 12 'Other Financial Instruments Issues. ol FRS 102 lo all ol its financial instnJments. Financial instruments recognised in the tharitys balance sheel when the ch8rity be(x)mes party to the contractual prowsions of the InstnJm8nt. Financial assets and liabilities offsel. wth the nel amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to setue on a net basis or to realise the asset and setue the liability simultaneously. Baslc Ilnanclal assets Basic financial assets. which indude debtors and cash and bank balances. are initially rneasured at lrans8cts.on price including transaction costs and are subsequenuy carried at amortised c05t Using the effective interest method unless the arrangement constitutes a finantyng transaction, where the Irarisactitsn is mèasurèd al thè prèseni valuè ol the future recèipts discount8d at 8 markèt ratè of interèst. Fin8na81 assèts classified as receivable within one year arè Th)t am0"Sd. Basic flnancial liabillties Basic financial Iiabililies. induding uaditots and bank an$ arè Initlally r•cognlsad at transaction prfc• unlass the arrangement conslilules a financing Iransaclion. where the debt instrument is measured al the present value ol the future payments discounted at a maikel late ol interest. Financial liabilitses classified as payable thin one year 8re not amortised. Tradg cr8ditors arè obligabon$ lo p8y go$ LY s¢rvieè$ thal hovè bgèn affjuirgd in tho ordinary cours¥ of operations from supplièrs. Amounts payable arè dasstfied as etsrrènt liabilitiès if paymanl is duè within on6 year or less. If not, they a presented as non-currenl liabilities. Trade creditors are recognised initially at transacts'on price and subsequenlly measured al amortised cost using the effeclive interest rnethod. 1.10 Taxatlon The charity is exempt from corporation lax on ils chariiable activi1. 1.11 Employee b¢nellts The cost of any unused holiday enlitlement is recognised in the wiod in which the employee's services are received. Terrnin8lion beneffts are re(gnIsed immeili81ety 8s an expense when the ch8rity is demonstrably cornmilled to tamiinatè thè èmploymènt ol an émployaè or to provid8 tèmination bènéfts. 1.12 P•nsion costs and oth•r post*•tir•m•nt b•n•ffts Payrnents to defineil Ixjntribution reb'refflenl benefft sthemes are charged as an expense as they fall due. 1.13 Fund aeeounting Unrestricted fvnds can be used in ac(x)rdance with the charilable oble5 * the discretion of the truste85. Restricted funds can only be used for particular $trIcted purposes wlhin the objects of the charity. Restrictions arise when speufied by the donor OT when fvnds are raised for particular restricted purposes. Further explanation of the nature and purwjse of each fvnd is indtKled in the notes to the financkgl staternents.
THE CANCER TREATMENT AND RESEARCH TRUST NOTES TO THE FINANCIAL STATEMENTS {CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025 Aeeounting pollelès IContlnu•d) 1.14 Current asset in¥eslments Current asset investments comprise fun¢Js held in short-tem bank deposit accounts lor the purpose of generating investment income. rather than meeting immediate operating wuirements. These deposits are measured al the amount deposiled. together wilh any accrued interest receivable where applicable. Income from donation and legacies Unr•strlded R•strfded fund$ fund$ 2025 2025 Total Unrèstrlcted Rèstrlcted fund$ fund$ 2024 2024 Total 2025 2024 Donations and gilts 289.876 11.015 300,891 384.379 100,182 484.561 Incom• from Inv•stm•nt Unr•8trlctod Unrfrstrlcted funds funds 2025 2024 Income frorn listed investments Int8r8St r8cèivabl¥ 496 24,384 646 16.944 24,880 17.590 Exp•ndltur• on r•lslng funds Unre8trfcted Unrestrlcted funds funds 2025 2024 Fundraising and publicity Seeking donations. grants and legacies 7,643 5,108 21
THE CANCER TREATMENT AND RESEARCH TRUST NOTES TO THE FINANCIAL STATEMENTS {CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025 Expenditure on charitable activities UF RF CharTrtable Charltable expenditure expenditure 2025 2025 Total Total 2025 2024 DSr•ct costs Research expenses and lab fees Conference and MeetiThJ 2.956 207,520 210,476 2,004 83,637 2.134 207,520 212,460 85.771 Trust•es N¢ irustees ts¢•ld remuntrralion for Ihtrir services. Employ••• The average monthly number ol employees during the year was.. 2025 Number 2024 Number There were no employees whose annual remuneration was more than £60,rx)o.
THE CANCER TREATMENT AND RESEARCH TRUST NOTES TO THE FINANCIAL STATEMENTS {CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025 Support and governance costs Support and govemance eosts represent expenditure vA)ich is not direclly attn"butable to a specific charitable activity but is necessary Ihe charity's overall operations and statutory compliance. Unr•strSded Unr•strlct•d funds funds 2025 2024 Subscription Travèl and subsistance Wages Social security costs Pension Insurance S18ff training Telephone Postag8 and stationary Advertising Computer expenses Daprèciation - pl8nt and machinery Depreciation - cornputer equipment Amortisalion Wèbsit• Bank ch8rges Entertainment Accountancy 188s 5,005 295 26.845 3.252 70 25.751 329 328 691 339 703 274 72 277 4,215 2,300 36 446 416 4,232 417 17,836 72 319 361 1.905 47 692 168 2,640 326 14,372 63,708 51,323 Support eosts repr8s¢nl the gtrneral admini$tr8tive expenditure Of Ihtr chanty. These ¢o$t$ ar8 allocated to an èxpenditur8 h88ding wherg the aclivity dITY banèfils (rnm such 4xnditurè,. whar8 allocation is not possible, the costs are shown vthhin supwl costs. Galns and losses on Investments Unre$tried Unrestri¢ted funds funds 2025 2024 Gainslllossesl arising on.. Rgvaluation of inv9Stments 51,834 The gain of £51,834 represents Ihe revaluation of the charitys listed sharehdding to its quoted market value at 31 D8C8tnb8r 2025. The inv85tsnent was pr8viously rarri8d at historical cost 8nd th8 gain ther8ft>r8 includes appreciation arising in earfier accountsng periods. 10 Taxatlon The charity is exempt from tsxation on its acti¥e5 because 811 ts in(x>rne is applied for charitable purposes. -23-
THE CANCER TREATMENT AND RESEARCH TRUST NOTES TO THE FINANCIAL STATEMENTS {CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025 11 Intangible fixed assets Web¥lt• Cost At 1 January 2025 Additions 1.858 4,200 At 31 Daeèmbèr 2025 6.058 Amortlsatlon and Impalmi•nt At 1 January 2025 Amortisation charged for the year 353 416 At 31 Decernber 2025 769 C•rrylng amount At 31 December 2025 5.289 At 31 Decernber 2024 1.505 12 Tanglble fixed ass•ls Pl4nt and ¢qulpffl•n¢ Comput•r• Total Cost At 1 January 2025 338 5,495 5,833 At 31 December 2025 338 S.495 5,833 Oepreclatlon and Impalmi•nt At 1 January 2025 Oeprecia¢ion charged in Ihe year 194 36 4,144 446 4,338 482 At 31 Decernber 2025 230 4,590 4,820 Carrying amount At 31 December 2025 108 1.013 At 31 Decernber 2024 144 1,350 1,494 -24-
THE CANCER TREATMENT AND RESEARCH TRUST NOTES TO THE FINANCIAL STATEMENTS {CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025 13 Fixed asset investments Listed invo$tmgnt$ Cost or valuation At 1 January 2025 Fair value adjustments 6.469 51.834 At 31 December 2025 58.303 Carrying amount At 31 December 2025 58.303 At 31 December 2024 6.469 14 O•btors 2025 2024 Amounts falling du• wthin on• y•ar: Trade debtors Other debtors Prepaymènts ¥nd a¢cru8d incom 1.861 21,192 9.744 1.721 8,553 32,797 10.274 15 Currént a88•t Inv•stm•nts 2025 2024 Bank deposit 765.979 The charity holds £765,97912024= £nill in bank deposit aoxunts. These funds resent surplus cash plad on deposit during the year to generaie investmenl inrne pending their application iowards future chariiable activities. 16 Cr•dltors'. amounts falllng du• wrthln on• y•ar 2025 2024 Other taxation and social security Trade creditors Other creditors Accruals and deferred incA)me 80 28,667 20,124 57 52.848 37,271 73,029 66,018 -25-
000 000 Voo *0 000 00(ry ¢J)r 000 OON ¢J) N ( 0)00 8 8X 8 O W) ¢ry m C io ggg ggg g=-g- C) > O q> q> J<
(LW > (o (LE o u CLZ(rJiZ(r(rJ_Ji)fLott EEwrLfiSJufLO<
THE CANCER TREATMENT AND RESEARCH TRUST NOTES TO THE FINANCIAL STATEMENTS {CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2025 19 Analysis of net assets between funds Unrestricted funds 2025 Restricted funds 2025 Total 2025 At 31 December 2025- Intangible fixed assets Tangible assets Investrnents Current assetsllliabilitiesl 5.289 1,013 58,303 1.221.038 5.289 1.013 58,303 1.574.589 353.551 1.285.643 353,551 1.639,194 Unr•8trletèd funds 2024 Rè8trlet•d funds 2024 Total 2024 At 31 Decomb•r 2024: Intangiblè lixod ass$l$ Tangible assets Investments Current 8ssetsllli8bililitr$l 1.505 1,494 6.469 1.194,710 1.505 1,494 6.469 1.535,952 341,242 1,204,178 341,242 1,54S,420 20 R•lated party tran8actlons The charity 18 required to disdlxe m•ieri81 related party tr8ns8C1ns under Ihe Ch8ri1ies SORP IFRS 1021. During thè y•ar'. No trustee received remuneration from the charity. Transactions wlh (Tuslees a disdosed in note 6. No Iwslees or persons ¢onrcled wilh Ihern had any personal interesl in any ntraCtS or Iran53¢tion5 enlered into by the charity. No other r6latail party transactic$ wuire disdosum.